Lilly expands Spanish-language section of ‘Lilly for Better Health’ Web portal
INDIANAPOLIS — Drug maker Eli Lilly has expanded its Spanish-language portal, the company said Friday.
Subsidiary Lilly USA launched an expanded "En Español" section of the Lilly For Better Health website. The section features a 60-page interactive health album that provides tips on healthy eating, physical activity and managing health conditions, as well as health-and-wellness quizzes and risk assessments on weight management, diabetes and other topics.
"Lilly is committed to serving our diverse patient population by providing disease prevention and management resources in multiple languages, including Spanish," Lilly VP for the company’s U.S. medical division Jack Harris said. "By expanding the Spanish resources available through Lilly for Better Health, we aim to support more patients and families in living a healthier lifestyle."
Diplomat, RainTree Oncology Services announce agreement
SAN DIEGO — Diplomat Specialty Pharmacy has signed an agreement with a provider of acquisition and management services for oral cancer drugs that the companies said would allow for better access to the drugs and related programs.
RainTree Oncology Services announced the agreement with Flint, Mich.-based Diplomat, saying it was building a network of community oncologists through which members will obtain drugs at contracted prices and that the agreement would improve access to clinical and medication management programs.
"We are honored to be chosen by RainTree to be their specialty pharmacy partner," Diplomat president and CEO Phil Hagerman said. "Working in close partnership with RainTree will facilitate enhanced services to RainTree physicians and improved outcomes for their patients. This model will secure access to complex oral oncolytics as well as implement drug-specific algorithms that will help mimic clinical trial efficacy."
Changes in healthcare economics have affected how community oncology practices operate, RainTree said, putting pressure on their ability to deliver services to patients. This, according to the company, can make acquisition and management of oral cancer drugs problematic because the drugs are expensive and often not fully reimbursed.
FDA approves Antares Pharma’s overactive bladder drug
PARSIPPANY, N.J. — The Food and Drug Administration has approved a topical gel made by Antares Pharma for overactive bladder.
Watson Pharmaceuticals announced Thursday the approval of oxybutynin gel in the 3% strength, which it will launch next year under a licensing agreement with Antares.
"This significant achievement represents Antares’ first [new drug application] approval and is the culmination of a development program managed successfully by our clinical and regulatory team, Antares president and CEO Paul Wotton said. "Watson Pharmaceuticals proven track record of commercializing transdermal products to urologists and other significant prescribers of [overactive bladder] treatments makes them an ideal partner to execute a successful product launch."